Celcuity Stock Hits All-Time High on Gedatolisib Trial Success
ByAinvest
Friday, Aug 15, 2025 12:43 pm ET1min read
CELC--
The PIK3CA wild-type cohort showed a 76% reduction in disease progression risk with the gedatolisib triplet therapy and a 67% reduction with the doublet therapy. This represents a potential paradigm shift in HR+/HER2- advanced breast cancer treatment, with hazard ratios (HR) of 0.24 and 0.33, respectively [2].
The PIK3CA mutant cohort is currently enrolling participants, with topline data expected by the end of 2025. Additionally, another phase III trial, VIKTORIA-2, is ongoing, evaluating the efficacy and safety of Gedatolisib in combination with fulvestrant and CDK4/6 inhibitors as a first-line treatment for endocrine therapy-resistant HR+/HER2- advanced breast cancer patients.
Celcuity's stock has seen a substantial increase, reflecting a gain of over 300% from its price of $12.60 in December 2024. The company's strong financial position, with a proforma cash position of $455 million, provides flexibility for the critical transition from development to commercialization [2].
References:
[1] https://www.rttnews.com/3566617/celcuity-stock-hits-all-time-high-on-gedatolisib-progress.aspx
[2] https://www.stocktitan.net/news/CELC/celcuity-inc-reports-second-quarter-2025-financial-results-and-kuvlwcp6udhp.html
Celcuity's stock has reached an all-time high of $53.85, driven by positive topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial for its lead drug candidate, Gedatolisib. The trial showed a reduction in risk of disease progression or death and an incremental improvement in progression-free survival for HR+/HER2-advanced breast cancer patients. The PIK3CA mutant cohort is enrolling participants, with topline data expected by year-end. Another phase III trial, VIKTORIA-2, is also ongoing.
Celcuity Inc. (CELC) saw its stock price hit an all-time high of $53.85 today, fueled by the positive topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial. The trial, which evaluated Gedatolisib in combination with fulvestrant and palbociclib for HR+/HER2-advanced breast cancer, demonstrated a significant reduction in risk of disease progression or death and an incremental improvement in progression-free survival [1].The PIK3CA wild-type cohort showed a 76% reduction in disease progression risk with the gedatolisib triplet therapy and a 67% reduction with the doublet therapy. This represents a potential paradigm shift in HR+/HER2- advanced breast cancer treatment, with hazard ratios (HR) of 0.24 and 0.33, respectively [2].
The PIK3CA mutant cohort is currently enrolling participants, with topline data expected by the end of 2025. Additionally, another phase III trial, VIKTORIA-2, is ongoing, evaluating the efficacy and safety of Gedatolisib in combination with fulvestrant and CDK4/6 inhibitors as a first-line treatment for endocrine therapy-resistant HR+/HER2- advanced breast cancer patients.
Celcuity's stock has seen a substantial increase, reflecting a gain of over 300% from its price of $12.60 in December 2024. The company's strong financial position, with a proforma cash position of $455 million, provides flexibility for the critical transition from development to commercialization [2].
References:
[1] https://www.rttnews.com/3566617/celcuity-stock-hits-all-time-high-on-gedatolisib-progress.aspx
[2] https://www.stocktitan.net/news/CELC/celcuity-inc-reports-second-quarter-2025-financial-results-and-kuvlwcp6udhp.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet